Loading...
•
Jun 30, 2020
Regeneron Q2 2020 Earnings Report
Reported a strong second quarter with revenue growth and advancements in clinical trials.
Key Takeaways
Regeneron reported a 24% increase in revenue to $1.95 billion for Q2 2020, driven by strong performance of key products like EYLEA and Dupixent. The company advanced its COVID-19 antibody cocktail, REGN-COV2, into late-stage clinical trials and saw FDA approval of Dupixent for children aged 6 to 11 years with moderate-to-severe atopic dermatitis. GAAP diluted EPS was $7.61, and non-GAAP diluted EPS was $7.16.
Second quarter revenues increased 24% to $1.95 billion compared to Q2 2019.
GAAP diluted EPS was $7.61 and non-GAAP diluted EPS was $7.16.
Advanced REGN-COV2, antibody cocktail for COVID-19, into late-stage clinical studies.
FDA approved Dupixent for children aged 6 to 11 years with moderate-to-severe atopic dermatitis.
Regeneron
Regeneron
Regeneron Revenue by Segment
Regeneron Revenue by Geographic Location
Revenue by Segment
Net Product Sales Revenue
CapyFin.comRevenue by Geographic Location
U.S. Net Product Sales Revenue
CapyFin.com Forward Guidance
Regeneron provided full year 2020 financial guidance.
Positive Outlook
- GAAP R&D: $2.605 billion–$2.725 billion (previously $2.150 billion–$2.310 billion)
- Non-GAAP R&D: $2.270 billion–$2.370 billion (previously $1.900 billion–$2.040 billion)
- GAAP SG&A: $1.400 billion–$1.480 billion (previously $1.380 billion–$1.500 billion)
- Non-GAAP SG&A: $1.210 billion–$1.270 billion (previously $1.190 billion–$1.290 billion)
- Effective tax rate (ETR): 9–11% (previously 10–12%)